he antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”“A draft manuscript was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is now undergoing peer review and we are waiting for a final version before WHO comments on it,” said WHO spokesperson Daniela Bagozzi.advertisementGilead...…he antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a “potential benefit.”“A draft manuscript was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is now undergoing peer review and we are waiting for a final version before WHO comments on it,” said WHO spokesperson Daniela Bagozzi.advertisementGilead...WW…

government-run study of Gilead’s , perhaps the most closely watched experimental drug to treat the novel coronavirus, showed that the medicine is effective against Covid-19, the disease caused by the virus.The finding — although difficult to fully characterize without full, detailed data for the study — would represent the first treatment shown to improve outcomes in patients infected with the virus that put the global economy in a standstill and killed at least 218,000 people worldwide.advertisementDuring an appearance alongside President Trump in the Oval Office, Anthony Fauci, the...…government-run study of Gilead’s , perhaps the most closely watched experimental drug to treat the novel coronavirus, showed that the medicine is effective against Covid-19, the disease caused by the virus.The finding — although difficult to fully characterize without full, detailed data for the study — would represent the first treatment shown to improve outcomes in patients infected with the virus that put the global economy in a standstill and killed at least 218,000 people worldwide.advertisementDuring an appearance alongside President Trump in the Oval Office, Anthony Fauci, the...WW…

Chicago hospital treating severe patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.advertisementadvertisementComments are closed.advertisementYou've been selected! Subscribe to STAT+ for less than $2 per daySubscribe to STAT+ for less than $2 per dayUnlimited access to the health care news and insights you need…Chicago hospital treating severe patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.advertisementadvertisementComments are closed.advertisementYou've been selected! Subscribe to STAT+ for less than $2 per daySubscribe to STAT+ for less than $2 per dayUnlimited access to the health care news and insights you needWW…

he participant who of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis, the drug maker’s chief executive, Pascal Soriot, said during a private conference call with investors on Wednesday morning.The woman’s diagnosis has not been confirmed yet, but she is improving and will likely be discharged from the hospital as early as Wednesday, Soriot said.The board tasked with overseeing the data and safety components of the AstraZeneca...…he participant who of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis, the drug maker’s chief executive, Pascal Soriot, said during a private conference call with investors on Wednesday morning.The woman’s diagnosis has not been confirmed yet, but she is improving and will likely be discharged from the hospital as early as Wednesday, Soriot said.The board tasked with overseeing the data and safety components of the AstraZeneca...WW…

large, Phase 3advertisementadvertisementadvertisementYou've been selected! Subscribe to STAT+ for less than $2 per daySubscribe to STAT+ for less than $2 per dayUnlimited access to the health care news and insights you need…large, Phase 3advertisementadvertisementadvertisementYou've been selected! Subscribe to STAT+ for less than $2 per daySubscribe to STAT+ for less than $2 per dayUnlimited access to the health care news and insights you needWW…